What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
John H. Rex mostly deals with Mycosis, Fluconazole, Microbiology, Amphotericin B and Internal medicine.
His Mycosis study is concerned with the larger field of Immunology.
His Fluconazole research includes elements of Itraconazole and Fungemia.
His Amphotericin B study integrates concerns from other disciplines, such as Anesthesia, Catheter, Intensive care medicine, Comparative trial and Pharmacology.
The study incorporates disciplines such as Primary therapy, Cancer and Cryptococcus neoformans in addition to Intensive care medicine.
The various areas that John H. Rex examines in his Internal medicine study include Gastroenterology and Surgery.
His most cited work include:
- Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. (2609 citations)
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus (2079 citations)
- Guidelines for Treatment of Candidiasis (1215 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Microbiology, Fluconazole, Amphotericin B, Intensive care medicine and Mycosis.
His Fluconazole study combines topics in areas such as Itraconazole, Candida glabrata and Pharmacotherapy.
His Amphotericin B research focuses on Pharmacology and how it connects with Drug resistance.
John H. Rex has included themes like Invasive candidiasis, Antifungal, Clinical trial and MEDLINE in his Intensive care medicine study.
His studies deal with areas such as Internal medicine and Aspergillosis as well as Mycosis.
His Internal medicine research incorporates elements of Gastroenterology and Surgery.
He most often published in these fields:
- Microbiology (35.20%)
- Fluconazole (32.40%)
- Amphotericin B (29.60%)
What were the highlights of his more recent work (between 2013-2021)?
- Antibiotic resistance (8.00%)
- Risk analysis (8.40%)
- Biotechnology (7.60%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Antibiotic resistance, Risk analysis, Biotechnology, Drug resistance and Microbiology.
John H. Rex combines subjects such as Economic growth, Antibiotics, Clinical trial, General partnership and Portfolio with his study of Biotechnology.
John H. Rex interconnects Pharmacokinetics, Drug development, Intensive care medicine, Pathogenic organism and Antifungal drug in the investigation of issues within Drug resistance.
His research integrates issues of White paper, Antimicrobial and MEDLINE in his study of Intensive care medicine.
His Microbiology research includes themes of In vitro and Trichosporon.
His work in Aspergillus covers topics such as Scedosporium which are related to areas like Amphotericin B.
Between 2013 and 2021, his most popular works were:
- Alternatives to antibiotics—a pipeline portfolio review (396 citations)
- Developmental roadmap for antimicrobial susceptibility testing systems (74 citations)
- Analysis of the clinical antibacterial and antituberculosis pipeline. (63 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Antibiotics
John H. Rex focuses on Biotechnology, Antibiotic resistance, Drug resistance, Economic growth and General partnership.
His Biotechnology research is multidisciplinary, incorporating elements of Antibiotics, Clinical trial, Antimicrobial, Intensive care medicine and Portfolio.
John H. Rex performs multidisciplinary study in Intensive care medicine and Active control in his work.
His work carried out in the field of Antibiotic resistance brings together such families of science as Antimycobacterial, Mycobacterium tuberculosis and Mode of action.
Drug resistance is a subfield of Microbiology that he studies.
His work on Reimbursement and Health care as part of general Economic growth study is frequently connected to Scale, Incentive and Health law, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
